Literature DB >> 31327585

OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.

Awss Zidan1, Cheryl Roe2, Devin Burke3, Luis Mejico3.   

Abstract

INTRODUCTION: The current standard-of-care protocol for OnabotulinumtoxinA (BoNTA) injections consists of fixed-site injections every 12 weeks. This pattern is based on clinical practice and extrapolated from BoNTA injections for other, non-migraine-related indications. It is unclear if this protocol is optimal for chronic migraine. In clinical practice, migraine patients frequently describe a period of increased headache frequency and intensity in the few weeks preceding their next injections. In order to evaluate the duration of the clinical effect of BoNTA injections in chronic migraine, we studied the variation in headache frequency on a weekly basis during the 12-week period following treatment in a cohort of migraine patients.
METHOD: 38 consecutive subjects were enrolled from an outpatient headache clinic, and asked to keep daily headache journals. 24 completed headache journals were analyzed. Headache frequency, duration and severity, as well as intake of symptomatic headache medications were recorded and compared among the different weeks.
RESULTS: The time-response plot following BoNTA injection was roughly U-shaped, with 3 distinct phases: an induction phase, a maximum efficacy phase, and a wear-off phase. The time-response plot revealed that the wear-off commenced around the eighth week post injection. The mean difference in the number of headache days per week between the first and the eighth week was 1.8 (95% CI [0.670-2.830], p = 0.003).
CONCLUSION: The effect of BoNTA injections on chronic migraines was not uniform throughout a 12-week period. A window of vulnerability to migraine attacks exist in the beginning and end of each cycle.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Induction; Maximum efficacy; Pharmacokinetics; Phase

Mesh:

Substances:

Year:  2019        PMID: 31327585     DOI: 10.1016/j.jocn.2019.07.043

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors:  Hsiangkuo Yuan; Stephen D Silberstein
Journal:  Handb Exp Pharmacol       Date:  2021

Review 2.  The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review.

Authors:  Christopher Gottschalk; Dawn C Buse; Michael J Marmura; Bradley Torphy; Jelena M Pavlovic; Paula K Dumas; Nim Lalvani; Andrew Blumenfeld
Journal:  Ther Adv Neurol Disord       Date:  2022-05-31       Impact factor: 6.430

3.  No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study.

Authors:  Andrew M Blumenfeld; Darko M Stevanovic; Mario Ortega; Joshua M Cohen; Michael J Seminerio; Ronghua Yang; Bo Jiang; Stewart J Tepper
Journal:  Headache       Date:  2020-10-28       Impact factor: 5.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.